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Coxsackie B virusThis study aimed at elucidating how Coxsackie B virus (CVB) perturbs the host’s microRNA (miRNA)
regulatory pathways that lead to antiviral events. The results of miRNA proﬁling in rat pancreatic
cells infection models revealed that rat rno-miR-466d was up-regulated in CVB infection.
Furthermore, in silico studies showed that Coxsackie virus and Adenovirus Receptor (CAR), a cellular
receptor, was one of the rno-miR-466d targets involved in viral entry. Subsequent experiments also
proved that both the rno-miR-466d and the human hsa-miR-466, which are orthologs of the
miR-467 gene family, could effectively down-regulate the levels of rat and human CAR protein
expression, respectively.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Coxsackie B viruses (CVB), belonging to the Human enterovirus
B cluster of the family Picornaviridae, are small, non-enveloped
viruses with a single-stranded 7.5 kb RNA genome containing a
30 poly(A) tail [1]. CVB are pathogenic viruses known to infect a
variety of organs, including the brain, intestines, heart, pancreas,
and lungs [2,3]. They cause meningoencephalitis, respiratory infec-
tion, myocarditis, acute pancreatitis, hand, foot and mouth disease
[4–7]. CVB infection can also cause birth defects and even infantile
deaths [8–10]. Recent studies showed that enterovirus infection
appeared to initiate or facilitate the pathogenic process leading
to type 1 diabetes (T1D) [4,11–13]. In T1D, there is selective loss
of the b cells within the pancreatic islets [14] which may be caused
by CVB infection [11–13].
Viral virulence is determined by successful entrance, replication
in the host cell, and release of mature virion [15]. Most viruses
enter mammalian cells by cell surface receptor-mediated processes
[15]. Coxsackie virus and Adenovirus Receptor (CAR; gene name:CXADR) is a type I membrane receptor for group B coxsackieviruses
and subgroup C adenoviruses. The CAR was originally found as a
cell surface protein enabling both viruses to interact with cells
[16,17]. It has been studied extensively for about two decades
since its discovery in 1997 [16,18–20]. Besides functioning as a
virus receptor, CAR was found to be differentially expressed in dif-
ferent tissues and in different developmental stages [21]. The CAR
protein was found to belong to the immunoglobulin superfamily
and functionally involved in tumorigenesis, apoptosis, cell adhe-
sion, fetal development, and essential for early embryonic cardiac
development [22–26]. Recently, CAR was discovered to play an
essential role in the development of the lymphatic vasculature in
the mouse embryo by promoting appropriate formation of lympha-
tic endothelial cell–cell junctions [27]. In another aspect, the
success of adenoviral oncolytic therapy also depends on the
expression of the CAR on tumor cells. It is suggested that CAR
expression analysis should be performed prior to adenoviral onco-
lytic treatment to stratify patients for treatment [28,29]. However,
no data are available about how the CAR expression is regulated.
Recent studies showed that small regulatory RNAs in mamma-
lian cells can regulate a multitude of cellular functions and
responses [30–35]. In particular, non-coding miRNAs, which are a
new class of 18–23 nucleotide long non-coding RNAs, have been
known to play critical roles in a wide spectrum of biological
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tebrates. Moreover, it has been demonstrated that miRNAs are
involved in different viral diseases, such as different miRNA expres-
sion proﬁles in human cells andmice infectedwith inﬂuenza viruses
that varied in virulence and pathogenicity [36,37]. Besides, small
RNA proﬁling of inﬂuenza A virus-infected cells identiﬁed miR-
449b as a regulator of histone deacetylase 1 and interferon beta
[38]. Moreover, in hepatitis C virus (HCV) infection, miRNAs can
inﬂuence viral life cycles both directly, through interactions with
the viral genome, and indirectly, through regulation of critical
virus-associated host pathways [39]. The miRNAs have also been
discovered to play an important antiviral role against HCV in mam-
malian cells [40], although the detailed mechanism remains
unknown. In West Nile virus (WNV) infection, miR-196a, miR-
202-3p, miR-449c, and miR-125a-3p are found to target multiple
genes that play a critical role in WNV neuropathogenesis [41].
Another miRNA – miR-155, is found to modulate Japanese enceph-
alitis virus (JEV)-induced neuroinﬂammation via targeting the Src
homology 2-containing inositol phosphatase 1 (SHIP1) 30 untrans-
lated region (UTR) [42]. As far aswe know, it remains a big challenge
to identify themolecular targets and biological functions ofmiRNAs.
This study aimed at elucidating how CVB perturbs the host’s
miRNA regulatory pathways which lead to antiviral events. We
hypothesized that miRNAs could be involved in CVB infection
responses and addressed this hypothesis using a miRNA micro-
array-based screening approach. Using miRNA proﬁling in two
mammalian infectionmodels, we identiﬁed a novel host cell miRNA
induced by CVB, namely miR-466. This miRNA may represent a
family of small RNAs that are inducible upon viral challenge. Our
results also showed that both human and rat miR-466 species can
down-regulate the expression of the CVB cellular receptor: CAR.
Our results will certainly provide useful information for the identi-
ﬁcation of novel intervention targets to ameliorate the adverse out-
come of CVB, or even Adenovirus infection through CAR regulation.2. Materials and methods
2.1. Virus isolates
Isolates of CVB were identiﬁed by indirect immunoﬂuorescence
assay (IFA) using monoclonal antibodies (Light Diagnostics
reagents from Millipore), PCR and viral genome sequencing. Stock
CVB B4 were then plaque-puriﬁed from Vero cells after isolation
from patients from the Prince of Wales Hospital, Hong Kong. The
stock viruses were stored in aliquots at 70 C, and were titred
by plaque assay. The research use of these samples was approved
by the Joint CUHK – NTEC Research Ethics Committee, Hong Kong.
2.2. Cell cultures
The clonal rat b-cell line INS-1E derived from parental INS-1
cells was cultured as described previously [43]. The RIN-5F cell line
(ATCC, CRL-2058, Rockville, MD, USA) was a clone derived from
the RIN rat islet cell line. The reason for using rat cell lines was
because there was no well establish human pancreatic cell line
which could secrete insulin upon glucose stimulation and suscep-
tible to CVB infection. The two rat cell line models – INS-1E and
RIN-5F, that we had used in our study were able to simulate the
situation in which the pancreatic b-cells were infected by CVB
leading to T1D, which is a disease characterized by the loss of insu-
lin producing b cells in the pancreatic islets of Langerhans.
A549 cells were derived from human alveolar basal epithelial
adenocarcinoma (ATCC, CCL-185). The A549 cell line was used
because this was a representative human cell line with high level
of CAR expression [44]. Therefore, this cell line was a suitablein vitro human model for us to study the effect of miRNA on CAR
mRNA and protein expression.
The HEK-293T cells derived from human embryonic kidney
(ATCC, CRL-11268) were also used in this study because it was
well known as highly transfectable cells and had been extensively
used as an expression tool for recombinant proteins since it was
generated over 25 years ago [45]. Therefore, in our study, we have
used HEK 293T cells for luciferase measurement experiments that
needed high transfection efﬁciency.
All these cells were cultured as described from the American
Type Culture Collection.
2.3. Infection of cells with CVB
INS-1E and RIN-5F cells were plated at 1  105 cells per well in
24-well plates. After 24 h, the cells were transfected with miRNA
mimics for 48 h as described in the transfection of miRNA mimics
section. The transfected or non-transfected cells were then inocu-
lated with CVB isolates at multiplicity of infection (m.o.i.) = 1. After
1 h of adsorption, the virus was removed and 0.5 ml of the previ-
ously saved miRNA transfection medium or fresh medium were
added, and incubated at 37 C in 5% CO2 humidiﬁed air.
2.4. RNA extraction
Total RNA and miRNA were extracted from normal and infected
RIN-5F, INS-1E cells and cell culture media using Trizol reagent
(Invitrogen, Carlsbad, CA), the Purelink RNA mini kit (Invitrogen)
and the Purelink miRNA isolation kit (Invitrogen) following the
manufacturers’ protocol, respectively. The RNA integrity was
assessed using Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA, USA).
2.5. Proﬁling of miRNA expression, statistical analysis of microarray
data and targets prediction
In our study, we wanted to study the effect of CVB infection of
pancreatic cells which might result in T1D. Due to the lack of avail-
ability of human cell line, we used the isolated human viruses to
infect rat cell line models in order to simulate infection in human
cells. The miRNAs were labeled using the Agilent miRNA labeling
reagent and hybridized to Agilent rat miRNA arrays (Microarray
Release 16.0) according to the manufacturer’s protocol as previ-
ously described [36]. Each miRNA array allowed us to interrogate
699 rat miRNAs. The results were analyzed using Genespring GX
12.5 software (Agilent Technologies). Target genes of the selected
signiﬁcant miRNAs were identiﬁed by TargetScan software and
database (http://www.targetscan.org/) which was integrated in
GeneSpring GX software. The context score percentile used for Tar-
getScan analysis was 90. A higher context score percentile meant
that a speciﬁc target site was more favorable than most other sites
of that miRNA [46–48].
2.6. MicroRNA proﬁling data resource
The data discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus [49] and are accessible through
GEO Series accession number GSE58692.
2.7. TaqMan real-time RT-PCR (qRT-PCR) for quantiﬁcation of miRNAs
Total RNA was reverse transcribed to cDNAwith looped miRNA-
speciﬁc RT primers contained in the TaqMan miRNA assays
(Applied Biosystems, Foster City, CA). Each cDNA was ampliﬁed
with sequence-speciﬁc primers in the TaqMan miRNA assays
(Applied Biosystems). PCR reactions were performed on an Applied
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tested in triplicate. The threshold cycle (Ct) values obtained with
the SDS software (Applied Biosystems) were compared with the
Ct obtained from 18S rRNA assay or U6 snRNA (Applied Biosys-
tems) for the normalization of total RNA input. The fold-change
was calculated based on Ct changes of mean medium Ct minus
individual Ct of a miRNA.
2.8. Transfection of miRNA mimics
The cultured cells were plated at 1  105 cells in 0.5 ml com-
plete medium per well in 24-well plates at 70–80% conﬂuence.
After 24 h, the cells were transfected with speciﬁc mirVana™ miR-
NA mimics, positive mimics, negative mimics controls (20 pmol/
well) (Ambion by life technologies, Austin, TX, USA), per well using
Lipofectamine RNAiMAX Transfection Reagent (Invitrogen). The
transfection efﬁciency was calculated from the percentage of ﬂuo-
rescent cells that were observed using ﬂorescence microscopy after
the transfection of ﬂuorescein isothiocyanate (FITC)-labeled short
nucleotide primers in separate controls. The transfection efﬁciency
was about 78.2 ± 6.3% (mean ± S.D.), which was considered to be
adequate for the functional analyses. Each experiment was per-
formed in triplicate.
2.9. Quantiﬁcation of CAR mRNA using qRT-PCR
In order to quantify the amount of the CAR mRNA in miRNA
transfected cells, total RNA was extracted and used as templates
for real-time PCR using CAR speciﬁc primers and probes with
SuperScript III Platinum One-Step Quantitative RT-PCR System
(Invitrogen). The primer and probe sequences were listed in Table 1
[50]. The expression of human or rat b-actin gene was also quanti-
ﬁed in a similar way for normalization. The primers and probes for
amplifying human and rat b-actin gene were listed in Table 1
(ShineGene Molecular Biotech, Inc., Shanghai, China). The expres-
sion level of the respective gene at the corresponding time point
in non-infected cells was regarded as one in the Comparative
delta–delta CT method [51].
2.10. Luciferase reporter gene constructs
Gene fragments were designed to test the predicted target
sequences of hsa-miR-466 and rno-miR-466d, respectively. The
gene fragments were designed to contain the 30-UTR of the human
CAR gene and the 30-UTR of the rat CAR gene. Since there were two
target sites predicted on the 30-UTR of the human CAR for hsa-miR-
466, the 30-UTR of the human CAR gene were divided into 2 sub-
fragments. Sub-fragment-1, named as hCAR-1, started from posi-
tion of nucleotide-1 to nucleotide-720; while sub-fragment-2,
named as hCAR-2, started from position of nucleotide-551 toTable 1
Primers and probes for quantitative real-time RT-PCR.
Primer/probe name Forward/reverse primer/probe Primer sequence (50–30)
H-actin-f Forward ACCGAGCGCGGCTACAG
H-actin-r Reverse CTTAATGTCACGCACGATTTC
H-actin-P Probe 6-FAM-TTCACCACCACGGCC
R-actin-f Forward AGGGAAATCGTGCGTGAC
R-actin-r Reverse CGCTCATTGCCGATAGTG
R-actin-P Probe 6-FAM-CTGTGCTATGTTGCCC
Human-CAR-F Forward AGAAGCTACATCGGCAGTAA
Human-CAR-R Reverse CTCTGAGGAGTGCGTTCAAA
Human-CAR-P Probe 6-FAM-CCATGTTGGAAGGAG
Rat-Cxadr-F Forward GAAGAGAAGTACGAGAAGGA
Rat-Cxadr-R Reverse AATGGTTGCTGCCGATGTA
Rat-Cxadr-P Probe 6-FAM-CACGACATCAGGGAAnucleotide-1259 with respect to the starting position of the 30-
UTR as nucleotide-1. The 30-UTR of the rat CAR gene only contained
509 nucleotides. It was designed in one fragment, named as rCAR-
1. The above gene fragments were purchased as gBlocks Gene Frag-
ments from the Integrated DNA Technologies (IDT, Coralville, IA,
USA). These fragments were then cloned into the pCR™2.1-TOPO
cloning vector using TOPO TA Cloning Kit (Invitrogen) for ampliﬁ-
cation purpose. The cloned fragments were then sub-cloned into
the PmeI and XbaI or PmeI and XhoI sites of the pmirGLO dual-lucif-
erase miRNA target expression vector (Promega, Madison, WI,
USA). The sub-cloned fragments were conﬁrmed by Sanger
sequencing (BGI, HK). The newly constructed pmirGLO plasmids
with individual miRNA target site were ampliﬁed and puriﬁed as
previously described. The plasmids obtained were named as h-
CAR-1-Luc, h-CAR-2-Luc and r-CAR-Luc, respectively.
2.11. Reporter plasmid transfection and luciferase assays
Transient transfection of HEK-293 cells were performed using
Lipofectamine 2000 (Invitrogen). For the luciferase assay, cells
were plated at a density of 1  105 cells per well in 24-well plates
and co-transfected after 24 h with 50 ng of pmirGLO reporter plas-
mid (Promega), as well as 20 pmol of miRNA mimics per well.
Luciferase activities were measured 48 h after transfection using
the Dual-Glo luciferase reporter assay system (Promega) and a Glo-
Max™ Vision 20/20 Luminometer (Promega). The binding of the
transfected miRNAs to the cloned miRNA target sequences would
reduce the ﬁreﬂy luciferase activity. The Renilla luciferase (hRluc-
neo) acted as a control reporter for normalization and selection.
For the calculation of the percentage of ﬁreﬂy luciferase activity/
Renilla luciferase activity of the tested miRNA, the corresponding
plasmid was co-transfected with or without negative control mim-
ics as negative controls. The negative controls that were without
transfection of any miRNA mimics were referenced as 100% ﬁreﬂy
luciferase activity/Renilla luciferase activities.
2.12. Western blot analysis
MirVana™ miRNA mimics or inhibitors transfected cell mono-
layers were lysed in radioimmunoprecipitation (RIPA) buffer sup-
plemented freshly with a cocktail of protease inhibitors (Roche,
Branford, CT, USA) and 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF), (Biosure, GrassValley, CA). The total protein concentration
was then determined by the bicinchoninic acid assay (BCA)
(Sigma–Aldrich, St. Louis, MO, USA). Proteins with equivalent con-
centration were resolved by 12% SDS–PAGE. The resolved proteins
were transferred to PVDF membrane (Bio-Rad, Hercules, CA, USA).
Rabbit antibodies were then used to probe for CAR (1:1000) (from
Santa Cruz Biotechnology, Santa Cruz, CA), with overnight incuba-
tion at 4 C. The membrane was subsequently incubated for 1 h atProduct length (bp) Target gene
59 Human actin conserved region
C
GAGC-TAMRA
145 Rat actin conserved region
TAGACTTC-TAMRA
TC 122 Human CAR gene
ACATGGACCC-TAMRA
AGTG 103 Rat CAR gene
GATGTGCCT-TAMRA
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oxidase-linked whole secondary antibody (Amersham Pharmacia
Biotech, Uppsala, Sweden). The membrane was also probed for
rat or human b-actin as a loading control (Millipore, Bedford, MA,
USA). The level of induction (n-fold) was calculated from the den-
sity values for protein bands relative to the b-actin results corre-
sponding to the untransfected control cells, the cells transfected
with negative control (NC), or the cells transfected with the
selected miRNA mimics as measured using ImageJ software [52].
2.13. Statistical analysis
In vitro experiments were performed in triplicate on at least 2
occasions. Results were given as mean ± S.D. Statistical analyses
were performed by using Student’s t-test, and the null hypothesis
was rejected at the 0.05 level.
3. Results and discussion
3.1. CVB infection consistently induced miRNA-466d expression
The pathogenic CVB B4 virus strain, and two cell line models
(INS-1E and RIN-5F cells) were used for infection in order to iden-
tify miRNAs that were affected by viral infection. The INS-1E and
RIN-5F were both rat pancreatic insulin-secreting b cell lines. In
both models, the cells were challenged with CVB B4 with
m.o.i = 1 for 1 h, followed by miRNA proﬁling using the Agilent
Rat miRNA Microarray Release 16.0, so as to identify any miRNAs
inducible by CVB B4. As shown in Table 2, we found that rno-
miR-466d (rno-miR is the nomenclature for rat miRNA) was mark-
edly up-regulated by 5.36 folds in the INS-1E cell model. The up-
regulation of rno-miR-466d was conﬁrmed by miRNA qRT-PCR
assays. We also found that in INS-1E cells, no miRNA was inducedTable 2
Differentially expressed miRNAs in CVB B4 virus infected INS-1E cells with (a) 48, (b)
72-h post-infection, and RIN-5F cells with (c) 48, (d) 72-h post-infection, respectively,
as detected by miRNA microarray technique and re-conﬁrmed by miRNA real-time
PCR.
(a) INS-1E cells 48-h post-infection #Mean fold-change Regulation
rno-miR-146a 3.09 Down
rno-miR-382 2.94 Down
(b) INS-1E cells 72-h post-infection #Mean fold-change Regulation
rno-miR-210 3.05 Up
rno-miR-29a 2.00 Up
rno-miR-32⁄ 3.92 Up
rno-miR-375 2.95 Up
rno-miR-382 3.84 Up
rno-miR-466b-5p 2.92 Up
rno-miR-466d 5.36 Up
(c) RIN-5F cells 48-h post-infection #Mean fold-change Regulation
rno-miR-345-3p 3.44 Down
rno-miR-375 5.20 Down
rno-miR-382 5.10 Down
rno-miR-466b-1-3p 2.43 Down
rno-miR-466d 2.34 Up
(d) RIN-5F cells 72-h post-infection #Mean fold-change Regulation
rno-miR-151 1.9 Down
rno-miR-375 21.51 Down
rno-miR-382 20.18 Up
# INS-1E and RIN-5F cells were infected with CVB B4 virus at m.o.i. = 1. qRT-PCR
were used to quantify the miRNA levels and fold-changes were calculated by DDCT
method as compared with non-infection cell control and using 18S rRNA level for
normalization. Each experiment was performed in triplicate. The mean fold-chan-
ges of miRNA in CVB B4 virus infected INS-1E or RIN-5F cells were compared to that
of the corresponding non-infected controls ± S.D. (P < 0.05), respectively.at 48-h, while 7 miRNAs were induced at 72-h upon a brief
exposure to CVB B4. In addition to rno-miR-466d, rno-miR-382
was also found to be up-regulated (at 72-h post-infection). How-
ever, rno-miR-382 was excluded for further characterization
because of its opposite expression pattern at earlier time point at
48-h, as well as the lack of prediction targets for viral entry
(Table 3). Similar experiment was performed in the RIN-5F cells.
It was found that at 48-h post-infection, ﬁve miRNAs showed dif-
ferential expression (Table 2). However, rno-miR-466d was the
only miRNA that was consistently induced and up-regulated in
RIN-5F cells upon exposure to CVB, while the other 4 miRNAs
(rno-miR-345-3p, rno-miR-375, rno-miR-382, and rno-miR-466b-
1-3p) were signiﬁcantly down-regulated. These results might fur-
ther suggest that there was a difference in the kinetics of miRNA
induction in these two cell models.3.2. Prediction of miRNA-466d targets by bioinformatics tools
The rno-miR-466d belongs to the miR-467 gene family. Target-
Scan integrated in the GeneSpring GX 10.0.2 software (Agilent
Technologies) was used for the target prediction of rno-miR-
466d, as well as all other miRNA species, with consistent and sig-
niﬁcant changes in expression following CVB B4 infection in both
cell lines (Table 2). Among all identiﬁable mRNA targets of rno-
miR-466d, the cell surface receptor CAR was the only target that
was related to viral entry. CAR was also well known to be the
essential receptor required for CVB infection [16,17,20]. Using Tar-
getScan, Clustal X 2.0, and Bioedit [46–48,53,54] we further located
the target site (‘‘seed’’ pairing region) of rno-miR-466d on the 30-
UTR of rat CAR mRNA at nucleotide-149 with respect to the start-
ing position of the 30-UTR (Fig. 1a). We therefore further examined
the potential targets of human miR-466, namely hsa-miR-466,
which is also an ortholog of the miR-467 gene family. Consistent
with our ﬁndings in the rat model, potential hsa-miR-466 binding
sites on the human CAR mRNA were successfully identiﬁed using
cross-species sequence comparison. Two ‘‘seed’’ pairing regions
of hsa-miR-466 were predicted to exist on the human CAR mRNA
at the positions of nucleotide-401 and nucleotide-1185 with
respect to the starting position of the 30-UTR (GenBank ID:
Y07593.1), suggesting that the human ortholog of rno-miR-466d
might also target the human CAR mRNA (Fig. 1b).
3.3. CAR expression down-regulated by hsa-miR-466 and rno-miR-
466d
To investigate if human CAR is the real endogenous target of
hsa-miR-466 as predicted by bioinformatics analyses, we exam-
ined the effects of hsa-miR-466 on the human CAR activity by lucif-
erase reporter assays. Both predicted target sites of the hsa-miR-
466 at the human CAR 30-UTR region (as depicted in Fig. 1a) were
cloned into the 50-end of a luciferase reporter gene, generating h-
CAR-1-Luc (nucleotide-1 to nucleotide-720 of the 30-UTR) and h-
CAR-2-Luc (nucleotide-551 to nucleotide-1259 of the 30-UTR)
reporter constructs for co-transfection assays with hsa-miR-466
mimics. As shown in Fig. 2a, hsa-miR-466 mimics signiﬁcantly
suppressed the luciferase activities of both h-CAR-1-Luc and h-
CAR-2-Luc reporters. Only 49% and 57%, respectively, of luciferase
activities were found to remain in the transfected HEK 293 cells as
compared with the vector controls. The same suppressive effect of
rno-miR-466d on the rat CAR activity was also demonstrated using
the r-CAR-Luc as the reporter construct carrying the predicted tar-
get site of the rat CAR messenger RNA (Fig. 1b). Comparing with
the vector control, only 59% luciferase activity was found to remain
after the co-transfection of rno-miR-466d mimics and r-CAR-Luc
into HEK-293 cells (Fig. 2b). All these results are consistent with
Table 3
Potential representative targets of selected miRNA. The potential targets of rno-miR-146a, rno-miR-210, rno-miR-29a, rno-miR-32⁄, rno-miR-345-3p, rno-miR-375, rno-miR-382,
rno-miR-465-3p, rno-miR-466b-1-3p, rno-miR-466b-5p, and rno-miR-466d are listed.
miRNA Target gene name Representative of predicted target sites
rno-miR-146a IRAK1 Interleukin-1 receptor-associated kinase 1
TRAF6 TNF receptor-associated factor 6
TDRKH Immunoglobulin superfamily, member 1
LRTOMT Leucine rich transmembrane and 0-methyltransferase domain containing
ZBTB2 Zinc ﬁnger and BTB domain containing 2
LRRC15 Leucine rich repeat containing 15
ZNF367 Zinc ﬁnger protein 367
RNASEL Zinc and ring ﬁnger 3
rno-miR-210 ANKRD34A Ankyrin repeat domain 34A
ZFYVE28 Zinc ﬁnger, FYVE domain containing 28
ZNF148 Zinc ﬁnger protein 148
SCRT1 Scratch homolog 1, zinc ﬁnger protein (Drosophila)
ELFN2 Extracellular leucine-rich repeat and ﬁbronectin type III domain containing 2
CPEB2 Cytoplasmic polyadenylation element binding protein 2
rno-miR-29a ATAD2B ATPase family, AAA domain containing 2B
BRWD3 Bromodomain and WD repeat domain containing 3
ZBTB5 Zinc ﬁnger and BTB domain containing 5
PURG Purine-rich element binding protein G
RNF19A Ring ﬁnger protein 19A
rno-miR-32⁄ CD69 CD69 molecule
SNX13 Sorting nexin 13
USP28 Ubiquitin speciﬁc peptidase 28
SSBP3 Single stranded DNA binding protein 3
CPEB3 Cytoplasmic polyadenylation element binding protein 3
PDZD2 PDZ domain containing 2
rno-miR-345-3p AKIRIN1 Akirin 1
TMEM79 Transmembrane protein 79
LRRTM1 Leucine rich repeat transmembrane neuronal 1
CNKSR2 Connector enhancer of kinase suppressor of Ras 2
ZNF516 Zinc ﬁnger protein 516
LHX1 LIM homeobox 1
RBM18 RNA binding motif protein 18
IL20RA Interleukin 20 receptor, alpha
rno-miR-375 SLC16A2 Solute carrier family 16, member 2 (monocarboxylic acid transporter 8)
ISL2 ISL LIM homeobox 2
RBM47 RNA binding motif protein 47
INSIG2 Insulin induced gene 2
EIF4G3 Eukaryotic translation initiation factor 4 gamma, 3
UBE3A Ubiquitin protein ligase E3A
rno-miR-382 TOP1 Topoisomerase (DNA) I
PDPK1 3-Phosphoinositide dependent protein kinase-1
ZNRF3 Zinc and ring ﬁnger 3
TCF7L2 Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box)
HSPA2 Heat shock 70kDa protein 2
TMEM131 transmembrane protein 131
MMP16 Matrix metallopeptidase 16 (membrane-inserted)
ZMYM2 Zinc ﬁnger, MYM-type 2
NRIP1 Nuclear receptor interacting protein 1
rno-miR-465-3p GOSR1 Golgi SNAP receptor complex member 1
PARP8 Poly (ADP-ribose) polymerase family, member 8
PRKRIR Protein-kinase, interferon-inducible double stranded RNA dependent
inhibitor, repressor of (P58 repressor)
ZMIZ1 Zinc ﬁnger, MIZ-type containing 1
BATF Basic leucine zipper transcription factor, ATF-like
UBE2S Ubiquitin-conjugating enzyme E2S
rno-miR-466b-1-3p/rno-miR-466b-5p GABRB3 Gamma-aminobutyric acid (GABA) A receptor, beta 3
ZFP91 Zinc ﬁnger protein 91 homolog (mouse)
ACVR2B Activin A receptor, type IIB
ZFAND3 Zinc ﬁnger, AN1-type domain 3
RBPMS RNA binding protein with multiple splicing
rno-miR-466d GABRB3 Gamma-aminobutyric acid (GABA) A receptor, beta 3
ZNF618 Zinc ﬁnger protein 618
GRID1 Glutamate receptor, ionotropic, delta 1
ARHGEF17 Rho guanine nucleotide exchange factor (GEF) 17
CXADR Coxsackie virus and Adenovirus Receptor
IGF1R Insulin-like growth factor 1 receptor
IGF2 Insulin-like growth factor 2 (somatomedin A)
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(a) (b)
Fig. 1. Predicted binding sites of rno-miR466d, and hsa-miR-466 on the 30-UTR of Rat and human CAR gene. The marked boxes show the miRNA ‘‘seed’’ pairing region on the
target sequences. The sequences shown in the ﬁgures start from the 1-nucleotide of the 30-UTR, respectively. (a) Predicted binding site of rno-miR-466d on the 30-UTR of rat
CAR gene (RCAR-3UTR). The GenBank accession number of the rat CAR reference sequence used is gb|BC088313.1| – Rattus norvegicus Coxsackie virus and Adenovirus
Receptor (CAR) mRNA, complete cds. The gene sequence length is 1693 nucleotides, whereas the coding sequence is from 72 to 1130-nucleotide. The 30-UTR is from 1131
to1693-nucleotides. (b) Predicted binding sites of hsa-miR466 on the 30-UTR of human CAR gene (HCAR-3UTR). The GenBank accession number of the human CAR reference
sequence used is gb|Y07593.1| – H. sapiens mRNA for 46kDa Coxsackievirus and Adenovirus Receptor (CAR) protein. The gene sequence length is 2434 nucleotides whereas
the coding sequence is from 60 to 1157-nucleotide. The 30-UTR is from1158 to 2434-nucleotide.
(a) (b)
Fig. 2. Normalized luciferase activities using the luciferase reporter vector with rat or human CAR 30-UTR target sequences. (a) Luciferase reporter plasmids containing
human CAR 30-UTR sequences which were potentially targeted by hsa-miR-466. Region from 1 to 720 bp of the human CAR 30-UTR was contained in the plasmid h-CAR-1-Luc,
while region from 551 to 1259 bp of the human CAR 30-UTR was contained in the plasmid h-CAR-2-Luc. (b) Luciferase reporter plasmids – r-CAR-Luc containing rat CAR 30-
UTR sequence which were potentially targeted by rno-miR-466d. (a, b) Reporter activities were determined 48 h post-transfection by Dual-Glo luciferase assay system, and
the resultant percentages are shown. Data are representative of at least three independent experiments, with each determination performed in triplicate (mean ± S.D. of
percentage change). The mean percentage-change of luciferase activities of constructed h/r-CAR-Luc reporter plasmids with miRNA mimics added samples were compared to
that of constructed h/r-CAR-Luc reporter plasmid only controls, respectively (P⁄ < 0.05).
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species.
Strikingly, hsa-miR-466 was found to have potent suppressive
effects on human CAR protein. At 48-h post-infection, transient
transfection of hsa-miR-466 was able to suppress the human CAR
protein expression by more than 58.3% when compared to the neg-
ative control (NC) (Fig. 3a, b). This dramatic reduction of human
CAR protein was accompanied by approximately 50% down-regula-
tion of CAR mRNA levels. Similar potent suppressive activity of
rno-miR-466d on rat CAR protein (suppressed by 88.9%) and mRNA
(suppressed by 1%) was also observed (Fig. 3c and d). The reason
why the rat CAR mRNA level only decreased by 1%, whereas the
rat protein was 88.9% suppressed, might be due to the translational
repression effect of the rno-miRNA-466d on rat CAR mRNA. It is
supported by the evidence that miRNAs could have two modes of
action: (1) translational repression, which is caused by, for exam-
ple, the disruption of translation initiation, thus inhibiting protein
translation of the target mRNA [55–57]; and (2) The miRNAs that
are partially complementary to a target could also speed up dead-
enylation, causing mRNAs to be degraded sooner [58]. In our stud-
ies, since the binding target sequences of miR-466 were different in
rat and human, it is possible that they had different preferred
modes of action on the affected mRNA being measured. Therefore,
this might explain the difference in suppression levels of CAR
mRNA in rat and human cells. Taken together, our results showed
for the ﬁrst time that miR-466 is an endogenous regulator of CAR
in both human and rat cells.
3.4. Putative mechanism of anti-CVB massive infection by regulating
CAR expression
CAR has been studied extensively for about two decades since
its discovery in 1997 [22–25]. However, no data is available about(a)
(b)
Fig. 3. The effect of ectopic overexpression of hsa-miR-466 and rno-miR-466d mimics in
The total protein from cell lysates was harvested at 48 h post-transfection of miRNA mim
untransfected control cells (CC), cells transfected with negative miRNA mimics control (N
rno-miR-466d. (a) The expression of human CAR protein was detected by using anti-CAR
level of human CAR mRNA in cells pre-transfected with hsa-miR-466 for 48 h. (c) The exp
INS-1E cells. (d) qRT-PCR showing the level of rat CAR mRNA in cells pre-transfected wit
was used as the loading control for each membrane prepared from the untransfected C
miRNA mimics. The results shown are representative of three separate experiments. T
protein bands relative to the b-actin results corresponding to the untransfected CC, the c
measured using ImageJ software. For the qRT-PCR results, each point on the graph represe
to that of CC and NC ± S.D. (P⁄ < 0.05; P# < 0.05; P++ < 0.05), respectively.how the CAR expression is regulated. In this study, we elucidated
miR-466 as the ﬁrst endogenous regulator of CAR in both rat and
human cells. CAR has been reported to have a half-life of only
about 20 min in Madin-Darby canine kidney (MDCK) epithelial
cells [59]. This is consistent with our ﬁndings that CAR protein
was markedly down-regulated in the presence of small amount
of hsa-miR-466.
Besides, mir-466 belongs to the gene family miR-467. Previous
studies of the gene family - miR-467, mainly focused on mouse
model. In mouse, miR-296-669 cluster belongs to the gene family
– mir-467. This cluster is located in intron 10 of the mouse Sfmbt2
gene on Chromosome 2 and is composed of more than 40 miRNAs
[60]. It had been shown that this cluster of miRNA was activated in
nutrient depleted conditions [61]. Recent report also showed that
one member of this cluster, mmu-miR-466h-5p, had a pro-apopto-
tic role through the targeting of several anti-apoptotic genes which
led to Caspase-3/7 activation and loss of cell viability. The expres-
sion of this miRNA was also shown to be activated during glucose
depletion. In another study, another member, mmu-miR-669c was
shown to be associated with the regulation of glutathione metab-
olism in the liver of aging mice [62]. Recent report also showed
that mmu-miR-466(a/e)-3p were important epigenetic regulators
of renal Nfat5 signaling, osmoregulation and urine concentration
in mice [63]. Therefore, this is the ﬁrst report showing the function
of miR-466 of the gene family – miR-467 in human.
We speculate that upon CVB infection, miR-466 expression
would be up-regulated in infected cells and this induction would
also occur in nearby not yet or non-infected cells. In this way, the
cell population might be protected from primary or secondary per-
sistence infection and/or superinfection by the invading viruses.
Our speculation is supported by the fact that CAR is an important
protein for tight junction formation between cells [21,59] and it is
also possible that CAR is involved in the transduction of signals to(c)
(d)
rat and human cell lines on the suppression of human or rat CAR expression. (a, c)
ics. Western blot analysis was performed to detect the expression of CAR protein in
C), and cells transfected with the corresponding miRNA mimics, i.e. hsa-miR-466 or
antibody in a human representative cell line - A549 cells. (b) qRT-PCR showing the
ression of rat CAR protein was detected by using anti-CAR antibody in a rat cell line –
h rno-miR-466d for 48 h. (a–d) For the Western blot analysis, rat or human b-actin
C, the cells transfected with NC mimics, and the cells transfected with the selected
he level of up or down-regulation (n-fold) was calculated from density values for
ells transfected with NC, or the cells transfected with the selected miRNA mimics as
nts the mean of fold-changes. The mean fold-changes of mRNA level were compared
W.Y. Lam et al. / FEBS Letters 589 (2015) 246–254 253nearby cells. Furthermore, down-regulation of CAR not only limits
viruses from utilizing this receptor for invasion, but also triggers
cell dissociation and ultimately lead to apoptotic cell death
[64,65], which will then cease the viral replication in infected cells.
Therefore this is the ﬁrst report to show that miR-466 might have
antiviral effects on CVB infection.
In conclusion, rno-miRNA-466d was induced in rat cells
exposed to CVB challenges. Moreover, miRNA-466 is identiﬁed
for the ﬁrst time as a regulator of CAR both in rat and human.
The potential of this miRNA for treating viral infection deserves
future investigation.Competing ﬁnancial interests
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